Investor Relations
Investor Presentation
View our latest Investor Presentation to find the most recent investor-related information.
View our latest Investor Presentation to find the most recent investor-related information.
For Fiscal Year Ending December 31, 2024
ÎåÐÇÌåÓýÖ±²¥ is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. ÎåÐÇÌåÓýÖ±²¥ enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesisâ„¢ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. ÎåÐÇÌåÓýÖ±²¥â€™ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications.